• Profile
Close

Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: Systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials

Journal of the American Heart Association Jun 13, 2019

Giugliano D, et al. - Researchers intended to clarify the significance of glycemic control and preexisting cardiovascular disease in assessing the risk of major cardiovascular events (MACE) in patients with type 2 diabetes mellitus. For this purpose, they analyzed cardiovascular outcome trials categorizing patients with or without preexisting cardiovascular disease. Only in patients with cardiovascular disease at baseline did findings reveal a lower risk of MACE. A significant 14% lower MACE risk in patients with preexisting cardiovascular disease and with a nonsignificant 2% higher MACE risk in those without preexisting cardiovascular disease correlated with the use of both glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors correlated vs placebo. In the treatment of patients with type 2 diabetes mellitus and overt cardiovascular disease, inclusion of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists is recommended, with attention paid to improving glycemic control, which could augment their advantage on MACE.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay